CD274 and tarsal-carpal coalition syndrome: Atezolizumab and Pembrolizumab have been approved for first-line systemic therapy for cisplatin-ineligible patients with local advanced or metastatic TCC whose tumors express PD-L1 (Balar et al., 2017a; Balar et al., 2017b).